Skip to main content

Month: July 2020

DNA Oyj:n puolivuotiskatsaus 2020: Tammi–kesäkuu sujui poikkeusoloista huolimatta hyvin – käyttökate ja liiketulos kasvoivat

DNA OYJ PÖRSSITIEDOTE 16.7.2020 KLO 8.30Tämä tiedote on tiivistelmä DNA:n puolivuotiskatsauksesta 2020. Puolivuotiskatsaus kokonaisuudessaan on tämän pörssitiedotteen liitteenä pdf-tiedostona ja verkkosivuillamme, osoitteessa www.dna.fi/sijoittajat.YhteenvetoSuluissa olevat luvut viittaavat vastaavaan ajanjaksoon vuotta aiemmin, ellei toisin mainita. Luvut ovat tilintarkastamattomia.DNA:n osakkeen listaus Nasdaq Helsingin pörssissä päättyi 3.2.2020 ja tämän jälkeen DNA ei ole arvopaperimarkkinalain mukaisen tiedonantovelvollisuuden piirissä osakkeiden liikkeeseenlaskijana. DNA on laskenut liikkeelle vuonna 2025 erääntyvän joukkovelkakirjalainan (ISIN: FI4000312095), joka on listattuna Nasdaq Helsingin pörssissä ja jonka suhteen DNA on edelleen tiedonantovelvollisuuden piirissä.Tammi–kesäkuu 2020Liikevaihto laski 1 % ja oli 459 miljoonaa...

Continue reading

Bufab Group: Interim report January – June 2020

Stable result despite a very weak market. Gradual recovery during the quarter. Cost savings program expanded to SEK 100 million. Focus on increased market share.Second quarter of 2020Net sales declined by 6 percent to SEK 1,022 million (1,089). Organic growthwas -25 percent and order intake was lower than net salesOperating profit (EBITA) declined to SEK 92 million (103) and the operating margin was 9.1 percent (9.5)Operating cash flow increased to SEK 116 million (94)Earnings per share declined to SEK 1.24 (1.91)The cost savings programme from 2019 was expanded to SEK 100 million, with full effect from January 2021January – June 2020Net sales rose by 7 percent to SEK 2,337 million (2,180). Organic growthwas -15 percent and order intake was lower than net salesOperating profit (EBITA) was SEK 218 million (222) and the operating margin...

Continue reading

Bufab Group: Delårsrapport januari – juni 2020

Stabilt resultat trots mycket svag marknad. Gradvis återhämtning under kvartalet. Besparingsprogram utökas till 100 MSEK. Fokus på ökad marknadsandel.Andra kvartalet 2020Nettoomsättningen minskade med 6 procent till 1 022 (1 089) MSEK. Den organiska tillväxtenvar -25 procent och orderingången var lägre än nettoomsättningenRörelseresultatet (EBITA) minskade till 92 (103) MSEK och rörelsemarginalen var 9,1 (9,5) procentDet operativa kassaflödet ökade till 116 (94) MSEKResultatet per aktie minskade till 1,24 (1,91) SEKBesparingsprogrammet från 2019 utökas till 100 MSEK, med full effekt från januari 2021Januari – juni 2020Nettoomsättningen ökade med 7 procent till 2 337 (2 180) MSEK. Den organiska tillväxtenvar -15 procent och orderingången var lägre än nettoomsättningenRörelseresultatet (EBITA) var 218 (222) MSEK och rörelsemarginalen...

Continue reading

Euronext receives clearance from the Danish Financial Supervisory Authority to acquire up to 100% of VP Securities, the Danish Central Securities Depository

EURONEXT RECEIVES CLEARANCE FROM THE DANISH FINANCIAL SUPERVISORY AUTHORITY TO ACQUIRE UP TO 100% OF VP SECURITIES, THE DANISH CENTRAL SECURITIES DEPOSITORYAmsterdam, Brussels, Dublin, Lisbon, Oslo and Paris – 16 July 2020 – Euronext, the leading pan-European exchange, today announces it has received the clearance from the Danish Financial Supervisory Authority to acquire up to 100% of VP Securities A/S1 (“VP Securities”) on 15 July 2020. Euronext welcomes this regulatory approval by the Danish FSA that was the only condition to complete the transaction.Euronext has already secured strong support from existing shareholders of VP Securities with shareholders representing 90.68% of the total shares2 having already accepted Euronext’s offer as of today.Euronext’s tag along offer to acquire the remaining shares in VP Securities will remain...

Continue reading

OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program

NANTES, France, July 16, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced it will receive a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community, dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This funding was awarded as part of the Metropolitan Fund to Support Health Innovations Linked to the COVID-19 Health Crisis, a €1 million fund created by Nantes Metropole for health innovations to address the COVID-19 health crisis.“We thank Nantes Metropole for supporting us with a grant that will allow us to accelerate the development of a vaccine candidate against COVID-19. Our teams are diligently working to finalize the preclinical phase of this program based on a T lymphocyte response that can last over time...

Continue reading

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptomsPortfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available Early access to treatment for managing  COVID-19 symptoms is critical to preventing healthcare system overloadBasel, July 16, 2020 — Today, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can...

Continue reading

Notification on convocation of joint stock company “Grindeks” Extraordinary General Meeting of shareholders

Notification on convocation of joint stock company “Grindeks” Extraordinary General Meeting of shareholdersThe Management Board of joint stock company “Grindeks”, registration number: 40003034935, legal address: 53 Krustpils street, Riga, Latvia, LV-1057 (hereafter – the Company), based on the request of the shareholder SIA “Liplat Holding” calls up and announces that Extraordinary General Meeting of Shareholders of the Company will take place on 18 August 2020 at 12.00 at premises of the Company, 53 Krustpils street, Riga, Latvia. Shareholder Registration will be open from 11.30. Agenda:On dividends payment.Considering the Covid-19 pandemic, with the aim to preserve health of shareholders, the Company’s employees as well as public in general, we encourage all shareholders to participate in the meeting in a written  mode prior to the...

Continue reading

Paziņojums par akciju sabiedrības „Grindeks” ārkārtas akcionāru sapulces sasaukšanu

Paziņojums par akciju sabiedrības „Grindeks” ārkārtas akcionāru sapulces sasaukšanuAkciju sabiedrības „Grindeks”, vienotais reģ. nr. 40003034935, juridiskā adrese: Krustpils iela 53, Rīga, LV-1057 (tālāk tekstā – Sabiedrība), valde pēc akcionāra SIA “Liplat Holding” pieprasījuma sasauc un paziņo, Sabiedrības ārkārtas akcionāru sapulce notiks 2020. gada 18. augustā plkst. 12.00 Sabiedrības telpās, Krustpils ielā 53, Rīgā, akcionāru reģistrācija no plkst. 11.30. Darba kārtība:Par dividenžu izmaksu.Ņemot vērā Covid-19 pandēmiju, lai aizsargātu akcionāru, Sabiedrības darbinieku un sabiedrības veselību kopumā, aicinām visus akcionārus akcionāru sapulcē piedalīties rakstveidā, pirms akcionāru sapulces aizpildot balsojuma veidlapu, kas vismaz 14 dienas pirms akcionāru sapulces būs pieejama Sabiedrības interneta mājaslapā www.grindeks.lv, Oficiālās...

Continue reading

Delivering critical services in demanding times

(Fornebu, 16 July 2020) «This quarter has brought unprecedented challenges for our customers and employees, as societies in the regions Telenor operates in have endured the COVID-19 pandemic and the impact of measures taken to stop it. In such a situation, providing our customers with critical services and ensuring our employees’ health and safety has been our first priority. Despite the challenges, I am proud to say that during the past months, Telenor has taken a leap within digitalisation. We are now further increasing our focus on touch free operations, digital customer interactions and new ways of working.Our operating model has given us flexibility to manage operations, cost and investments, contributing to an EBITDA growth of 1 percent and free cash flow of NOK 4 billion in the quarter. As expected, lockdowns have affected prepaid...

Continue reading

Telenor opprettholder kritiske tjenester i en utfordrende tid

(Fornebu, 16. juli 2020) «Både kunder og ansatte har opplevd ekstraordinære utfordringer dette kvartalet. Alle de ni landene hvor Telenor er tilstede har gått gjennom COVID-19-pandemien og opplevd effektene av tiltakene som ble igangsatt for å stoppe den. Vår hovedprioritet har vært å opprettholde samfunnskritiske tjenester og sørge for ansattes trygghet og helse. På tross av disse utfordringene er jeg stolt av at Telenor har gjort store fremskritt. Vi akselererer arbeidet mot automatisk drift, digitale kundereiser og nye måter å jobbe på.Vår organisasjonsmodell har gitt oss fleksibilitet nok til å gjennomføre nødvendige operasjonelle justeringer og tilpasninger i kostnadsbasen og investeringene. Det har bidratt til en EBITDA-vekst på 1 prosent i kvartalet og en fri kontantstrøm på 4 milliarder kroner. Som ventet førte COVID-19-nedstengninger...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.